IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?

DSpace/Manakin Repository

IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?

Show simple item record

dc.contributor.advisor Peter Hutt en_US
dc.contributor.author Sullivan, Katherine
dc.date.accessioned 2012-05-19T22:04:17Z
dc.date.issued 2011
dc.identifier.citation Katherine Sullivan, IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing? (2011). en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8789615
dc.description.abstract ABSTRACT In an era of increased scrutiny of laws regulating corporate speech, state and federal regulators must balance regulation of the prescription drug market with the budgetary and public health needs. One area of contention is the use of prescriber data for pharmaceutical marketing. Claiming a need to protect physician privacy and the state budget, Vermont limited access to this data. Pharmaceutical companies and data processors filed suit, claiming a violation of their First Amendment rights. The Supreme Court recently heard the case. The outcome could have broad implications not only for states’ ability to protect privacy but also for FDA’s restrictions on pharmaceutical marketing. If the Supreme Court chooses to invalidate Vermont’s law, FDA’s regulation of off-label promotion could be ripe for a judicial challenge. en_US
dash.license LAA
dc.subject human drugs>>prescription drug promotion>>physician advertising en_US
dc.subject.other Food and Drug Law en_US
dc.title IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing? en_US
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-05-19T22:04:17Z

Files in this item

Files Size Format View
Sullivan, Katie FDA Final Paper.pdf 207.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters